Association of vascular endothelial growth factor gene polymorphism with the risk of non-small-cell lung cancer in an Iranian population
Session type: Poster / e-Poster / Silent Theatre session
Lung cancer is a leading cause of deaths from malignancy worldwide, due to its high incidence and lack of effective treatment. Despite the advances achieved in diagnosis and treatment in the last decades, the overall prognosis of lung cancer remains poor. Vascular endothelial growth factor (VEGF), an important regulator of angiogenesis and vascular permeability, is involved in various steps of many malignancies. VEGF inhibitors have become the key target of treatment of several cancers, including non-small-cell lung cancer (NSCLC). Gene polymorphisms within the gene encoding VEGF have been shown to be associates with an adverse outcome in various malignancies including NSCLC. The polymorphisms in the promoter region (-460 C/T) and 5'-untranslated region (+405 C/G) have been associated with different levels of VEGF expression. In this study we evaluated whether two polymorphisms -460 C/T and +405 C/G in VEGF gene are related with the susceptibility of NSCLC in an Iranian population.
Genomic DNA derived from 223 patients with NSCLC and 253 healthy controls were analyzed by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP).
There was no significant difference in the VEGF -460 C/G genotypes and allele frequencies between control and patients with NSCLC. However, an increased frequency of the +405 CC genotype was observed in the patients with NSCLC as compared to normal control groups (CC genotype versus CG plus GG genotypes; P<0.001). The +405 C allele was significantly associated with the presence of NSCLC (OD=1.90 and 95% CI= 0.9-2.4).
The results from this study show that the +405 C/T polymorphism in VEGF may be associated with higher risk of NSCLC in our population.